{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:50:31Z","timestamp":1793994631005,"version":"4.8.0"},"reference-count":49,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"unspecified","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2026,2,22]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Biologics for systemic lupus erythematosus (SLE) demonstrate variable treatment responses across trials. We evaluated baseline biomarkers as predictors of response to guide personalised therapy selection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed, OVID, Scopus, Cochrane and PsycInfo (January 2000\u2013October 2025) for randomised controlled trials (RCTs) evaluating biologics (anti-BAFF, JAK inhibitors, anti-interferon, anti-IL-12\/23, BTK inhibitors and T-cell modulators) in adult SLE patients. Primary outcomes included SLE Responder Index-4 response and time-to-flare. We performed random-effects meta-analysis stratified by interferon gene signature (IGS), serologic activity (anti-double-stranded DNA positivity and\/or low complement) and high disease activity (Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) \u226510), with false discovery rate correction for multiple comparisons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-one RCTs (17\u2009374 participants) were included. Overall, biologics improved SLE Responder Index-4 response versus control (risk ratio (RR) 1.26, 95%\u2009CI 1.19 to 1.33, p &lt;0.0001). Serologically active disease showed the strongest predictive value (RR 1.45, 95% CI 1.28 to 1.63, p&lt;0.0001, I\u00b2=0%, number needed to treat (NNT)=6.5). High baseline SLEDAI \u226510\u2009also predicted response (RR 1.22, 95% CI 1.13 to 1.32, I\u00b2=0%). IGS showed non-significant trends (RR 1.39, 95% CI 0.97 to 2.00, p=0.074, I\u00b2=68.5%). Efficacy varied by mechanism, with anti-BAFF agents showing consistent benefit (RR 1.35, 95% CI 1.26 to 1.45). Biologics reduced serious adverse events (SAE) (RR 0.90, p=0.009); this should be interpreted considering lupus flares contribute to SAE counts. Individual non-disease adverse events showed expected patterns, with herpes zoster significantly increased (RR 1.19, p=0.017).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Serologically active disease and high baseline disease activity significantly predict biologic therapy response with zero heterogeneity, while IGS showed inconsistent predictive value. These findings support using serological markers to guide biologic selection in real-world practice settings. Biologics demonstrate favourable safety profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD420251247531.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/lupus-2025-001920","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:15:16Z","timestamp":1773245716000},"page":"e001920","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Biomarker-stratified efficacy and safety of biologics in systemic lupus erythematosus: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"13","author":[{"given":"Safi G","family":"Alqatari","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Eastern Province, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5412-046X","authenticated-orcid":false,"given":"Mohanad A","family":"Alkuwaiti","sequence":"additional","affiliation":[{"name":"College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Eastern Province, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal A","family":"Al-Harbi","sequence":"additional","affiliation":[{"name":"College of Medicine, Qassim University, Buraydah, Al Qassim, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marj M","family":"Alabdullah","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Eastern Province, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel A","family":"Zeidan","sequence":"additional","affiliation":[{"name":"College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Eastern Province, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor H","family":"AlYousef","sequence":"additional","affiliation":[{"name":"College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Eastern Province, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A","family":"Alsaad","sequence":"additional","affiliation":[{"name":"College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Eastern Province, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena Y","family":"Abualjamal","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feras Ahmed","family":"Alkuwaiti","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Eastern Province, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah A","family":"Al-Abdulwahab","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Eastern Province, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajer Musaab","family":"AlZuhair","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Eastern Province, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danya Y","family":"AlNujaidi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Eastern Province, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora A","family":"Alasaker","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Eastern Province, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal A","family":"Hasan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Eastern Province, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Y","family":"Azzam","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, West Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"2026031109151207000_13.1.e001920.1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223035"},{"key":"2026031109151207000_13.1.e001920.2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-043021-032611"},{"key":"2026031109151207000_13.1.e001920.3","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16091176","article-title":"Biologics in Systemic Lupus Erythematosus: Recent Evolutions and Benefits","volume":"16","author":"Kundnani","year":"2024","journal-title":"Pharmaceutics"},{"key":"2026031109151207000_13.1.e001920.4","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(22)00332-0"},{"key":"2026031109151207000_13.1.e001920.5","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.70022","article-title":"Biomarkers for systemic lupus erythematosus: A scoping review","volume":"12","author":"Zhang","year":"2024","journal-title":"Immun Inflamm Dis"},{"key":"2026031109151207000_13.1.e001920.6","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1093\/rheumatology\/keaf145","article-title":"Belimumab efficacy in mucocutaneous manifestations of systemic lupus erythematosus: a large post hoc analysis of five phase III clinical trials","volume":"64","author":"Grosso","year":"2025","journal-title":"Rheumatology"},{"key":"2026031109151207000_13.1.e001920.7","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s12016-025-09082-x","article-title":"Efficacy and Safety of Biologics for Systemic Lupus Erythematosus (SLE): A Systematic Review and Network Meta-Analysis","volume":"68","author":"Ding","year":"2025","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026031109151207000_13.1.e001920.8","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026031109151207000_13.1.e001920.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.34400"},{"key":"2026031109151207000_13.1.e001920.10","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-005444","article-title":"Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteria","volume":"11","author":"Parodis","year":"2025","journal-title":"RMD Open"},{"key":"2026031109151207000_13.1.e001920.11","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00317-9"},{"key":"2026031109151207000_13.1.e001920.12","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225445"},{"key":"2026031109151207000_13.1.e001920.13","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/annrheumdis-2021-221425","article-title":"Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials","volume":"81","author":"Vital","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026031109151207000_13.1.e001920.14","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312463110"},{"key":"2026031109151207000_13.1.e001920.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2005.00219.x"},{"key":"2026031109151207000_13.1.e001920.16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu326"},{"key":"2026031109151207000_13.1.e001920.17","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9825-6"},{"key":"2026031109151207000_13.1.e001920.18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40744-016-0047-x","article-title":"First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study","volume":"3","author":"Schwarting","year":"2016","journal-title":"Rheumatol Ther"},{"key":"2026031109151207000_13.1.e001920.19","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s40744-020-00243-2","article-title":"Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies","volume":"7","author":"Collins","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2026031109151207000_13.1.e001920.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225686"},{"key":"2026031109151207000_13.1.e001920.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224854"},{"key":"2026031109151207000_13.1.e001920.22","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026031109151207000_13.1.e001920.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02607-1"},{"key":"2026031109151207000_13.1.e001920.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02546-6"},{"key":"2026031109151207000_13.1.e001920.25","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1053\/j.ajkd.2022.06.013","article-title":"Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population","volume":"81","author":"Yu","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"2026031109151207000_13.1.e001920.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220920"},{"key":"2026031109151207000_13.1.e001920.27","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/art.41900","article-title":"Phase III\/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus","volume":"74","author":"Ginzler","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2026031109151207000_13.1.e001920.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221478"},{"key":"2026031109151207000_13.1.e001920.29","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1136\/ard-2022-222858","article-title":"Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus","volume":"81","author":"van Vollenhoven","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026031109151207000_13.1.e001920.30","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/art.41811","article-title":"Efficacy, Safety, and Pharmacodynamic Effects of the Bruton\u2019s Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"73","author":"Isenberg","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026031109151207000_13.1.e001920.31","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00578-x"},{"key":"2026031109151207000_13.1.e001920.32","doi-asserted-by":"publisher","DOI":"10.7326\/M21-2078"},{"key":"2026031109151207000_13.1.e001920.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196"},{"key":"2026031109151207000_13.1.e001920.34","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30076-1"},{"key":"2026031109151207000_13.1.e001920.35","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213032"},{"key":"2026031109151207000_13.1.e001920.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32167-6"},{"key":"2026031109151207000_13.1.e001920.37","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211631"},{"key":"2026031109151207000_13.1.e001920.38","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/art.39856","article-title":"Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials","volume":"69","author":"Clowse","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026031109151207000_13.1.e001920.39","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an Anti\u2013Interferon\u2010\u03b1 Receptor Monoclonal Antibody, in Moderate\u2010to\u2010Severe Systemic Lupus Erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026031109151207000_13.1.e001920.40","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026031109151207000_13.1.e001920.41","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207653"},{"key":"2026031109151207000_13.1.e001920.42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208562"},{"key":"2026031109151207000_13.1.e001920.43","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207654"},{"key":"2026031109151207000_13.1.e001920.44","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205067"},{"key":"2026031109151207000_13.1.e001920.45","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202760"},{"key":"2026031109151207000_13.1.e001920.46","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613"},{"key":"2026031109151207000_13.1.e001920.47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2"},{"key":"2026031109151207000_13.1.e001920.48","doi-asserted-by":"publisher","DOI":"10.1002\/art.27601"},{"key":"2026031109151207000_13.1.e001920.49","doi-asserted-by":"publisher","DOI":"10.1002\/art.24699"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2025-001920","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:15:19Z","timestamp":1773245719000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2025-001920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,11]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/lupus-2025-001920"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2025-001920","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}